Product
Cemdisiran
Aliases
ALN-CC5
8 clinical trials
6 indications
Indication
Paroxysmal Nocturnal HemoglobinuriaIndication
Myasthenia GravisIndication
IgA NephropathyIndication
IgA nephropathyIndication
GlomerulonephritisIndication
IgAClinical trial
A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia GravisStatus: Recruiting, Estimated PCD: 2025-08-29
Clinical trial
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal HemoglobinuriaStatus: Recruiting, Estimated PCD: 2029-05-23
Clinical trial
An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal HemoglobinuriaStatus:
Clinical trial
A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Currently Treated With Eculizumab or RavulizumabStatus: Terminated, Estimated PCD: 2023-07-12
Clinical trial
A Single Arm, Open-Label Study to Assess the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab TherapyStatus: Completed, Estimated PCD: 2022-05-05
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA NephropathyStatus: Terminated, Estimated PCD: 2022-03-17
Clinical trial
A Randomized, Open-label, Two-arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyStatus: Completed, Estimated PCD: 2022-10-25